The article focuses on the need of the management of the legal panel system of the pharmaceutical company Pfizer after the collapse of merger with Allergan after new rules on tax inversions in the U.S. It mentions that efforts of the legal director Darren Noseworthy to increase integration of firms with the business by having a small number of firms managing. It also mentions that Pfizer's in-house legal team can turn to a panel arrangement
© 2001-2024 Fundación Dialnet · Todos los derechos reservados